Strategic Center for Clinical Cancer Research Clinical Cancer Research using Emerging Advanced Technologies for Health Title Slide

Strategic Center for Clinical Cancer Research Lancet: 365,1727,2005 Breast Cancer Mortality in Women,

Strategic Center for Clinical Cancer Research Proteomics Tumour biology Nano technologyBioinformatics Genomics Clinical Oncology The CREATE Health team

Strategic Center for Clinical Cancer Research CREATE Health Board Representatives from Lund University and Industry Director Carl Borrebaeck Deputy Carsten Rose Bioinformatics C Peterson DNA/RNA arrays Å Borg RNA/protein arrays C Borrebaeck Nano- technology T Laurell Clinical Oncology C Rose Tumor cell biology S Påhlman J Häkkinen J Vallon C Rovira Proteomics P James Scientific Advisory BoardSteering Committee IPR Review boardAdministration F Levander G Marko-Varga J Nilsson C Graffman M Ridderheim H Axelson C Larsson Scientific Secretary Financial Officer S Ek C Wingren Organisation

Strategic Center for Clinical Cancer Research Localisation of BMC and USil

Strategic Center for Clinical Cancer Research You are here! Localisation at the Biomedical Centre

Strategic Center for Clinical Cancer Research To create an integrative approach to solve complex clinical problems, by developing novel techniques - ”from bedside to bench and back again” To create a substantial social impact for the patient through direct application of research for selection of an optimal, individually-based, cancer treatment Mission and Vision Statements

Strategic Center for Clinical Cancer Research Clinical focus To associate specific gene and/or protein signatures with: Treatment-induced drug resistance Treatment response & optimisation Tumour relapse & survival time To identify novel targets for antibody-based therapy Research and Development

Strategic Center for Clinical Cancer Research Sample handlingTechnology development & application Sample collection Sample analysis Data analysis & mining Sample storage & tracking Sample processning Diagnostics/Treatment ClinicCREATE Health CentreClinic Investigators: Carl Borrebaeck Åke Borg Peter James Thomas Laurell Carsten Peterson Sven Påhlman Carsten Rose Clinical transfer Diagnostic validation Treatment validation Technology development CREATE Health Work flow

Strategic Center for Clinical Cancer Research Improved diagnosis Increased analytical sensitivity and capacity Improved prediction of disease progression Proteome-wide biomarker identification from fine needle/sure-cut biopsies Increased survival Disease stratification and tailoring of therapy Tumour specific antibodies for therapy Benefits for the patients

Strategic Center for Clinical Cancer Research Genomics focus define gene defects that are hereditary define chromosomal defects arising in cancer develop pathway focused gene monitoring methods find novel microRNA markers of cancer Proteomics focus discover protein markers of disease in cancer cells validate markers in serum for subsequent blood tests develop peptide monitoring for plasma analysis Discovery Projects

Strategic Center for Clinical Cancer Research Antibody microarrays antibody microarray based oncoproteomics nanostructured high performance chips for fluorescence/MS protein sampling in nanoscale for LCM single cell proteome Proteomic data basis & tools BASE & Proteios integrated algorithms for breast & lymphomas Cell reconstruction & validation Practical Application Projects

Strategic Center for Clinical Cancer Research Principle of Antibody Microarrays

Strategic Center for Clinical Cancer Research Analysis of serum proteomes from 30 pancreatic carcinoma patients and 15 healthy individuals red - upregulated black - no change green - down regulated 100% Sensitivity 100% Specificity Practical Example:Pancreatic Adenocarcinomas HealthyCarcinoma

Strategic Center for Clinical Cancer Research CREATE Health is actively engaged in developing its discoveries to benefit society and has a special board for IP issues. The CREATE Health team has generated > three world- wide patents/year over the past five years, ranging from basic research to applied biomedical inventions As a result, six spin-off firms have been created, some with > 100 employees. Technology Transfer and Commercialisation

Strategic Center for Clinical Cancer Research End Slide